Cargando…

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study

PURPOSE: Metastatic endocrine-resistant breast cancer (MBC) is a disease with poor prognosis and few treatment options. Low lymphocyte count is associated with limited overall survival. In a prospective cohort of lymphopenic patients with HER-2 negative MBC, we assessed the clinical and biological i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mery, Benoîte, Ménétrier-Caux, Christine, Montané, Laure, Heudel, Pierre-Etienne, Ray-Coquard, Isabelle, Bachelot, Thomas, Derbel, Olfa, Augereau, Paule, Treilleux, Isabelle, Berthet, Justine, Nkodia, Axelle, Bardin-Dit-Courageot, Christine, Attignon, Valery, Ferrari, Anthony, Garin, Gwenaele, Perol, David, Caux, Christophe, Dubois, Bertrand, Trédan, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150792/ https://www.ncbi.nlm.nih.gov/pubmed/37139242 http://dx.doi.org/10.2147/BCTT.S400055

Ejemplares similares

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
por: Verronèse, E., et al.
Publicado: (2015)

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
por: Ménétrier-Caux, Christine, et al.
Publicado: (2019)

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
por: Cassier, Philippe A, et al.
Publicado: (2011)

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
por: Manuel, Manuarii, et al.
Publicado: (2012)

CD73 expression and clinical significance in human metastatic melanoma
por: Monteiro, Inês, et al.
Publicado: (2018)

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2003)

MDR1 in immunity: friend or foe?
por: Bossennec, Marion, et al.
Publicado: (2018)

MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE
por: Di Roio, Anthony, et al.
Publicado: (2023)

Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial
por: Gouez, Manon, et al.
Publicado: (2022)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

CD163(+) tumor‐associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes
por: Ramos, Rodrigo Nalio, et al.
Publicado: (2020)

A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study
por: Hodroj, Khalil, et al.
Publicado: (2023)

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
por: Ménétrier-Caux, Christine, et al.
Publicado: (2012)

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
por: Bachelot, T, et al.
Publicado: (2006)

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells
por: Faget, Julien, et al.
Publicado: (2013)

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
por: Vigano, Selena, et al.
Publicado: (2019)

Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients
por: Sisirak, Vanja, et al.
Publicado: (2013)

Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
por: Cinier, Justine, et al.
Publicado: (2021)

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012)

Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response
por: Chapellier, Marion, et al.
Publicado: (2015)

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
por: Hodroj, Khalil, et al.
Publicado: (2021)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
por: Burlion, Aude, et al.
Publicado: (2019)

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
por: Belbaraka, Rhizlane, et al.
Publicado: (2010)

Validation of prognostic scores for survival in cancer patients beyond first-line therapy
por: Trédan, Olivier, et al.
Publicado: (2011)

Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
por: Mery, Benoîte, et al.
Publicado: (2021)

A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial
por: Delrieu, Lidia, et al.
Publicado: (2018)

Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients
por: Heudel, Pierre, et al.
Publicado: (2022)

New developments in treatment of ovarian carcinoma: focus on trabectedin
por: Cassier, Philippe A, et al.
Publicado: (2010)

Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer
por: Delrieu, Lidia, et al.
Publicado: (2021)

Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production
por: Bossennec, Marion, et al.
Publicado: (2019)

RESPONSE OF LYMPHOPENIC PLATELETPHERESIS DONORS TO COVID-19 VACCINATION
por: Bazin, Renee, et al.
Publicado: (2023)

Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study
por: Delrieu, Lidia, et al.
Publicado: (2020)

Renal cell carcinoma induces interleukin 10 and prostaglandin E(2) production by monocytes
por: Ménétrier-Caux, C, et al.
Publicado: (1999)

Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19
por: Kroemer, Alexander, et al.
Publicado: (2020)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection
por: Bermejo-Martin, Jesús F, et al.
Publicado: (2020)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
por: Trédan, Olivier, et al.
Publicado: (2023)

Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial
por: Delrieu, Lidia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25gv6oi4jjreq33lo2ru44an8q